Stifel Nicolaus Forecasts Strong Price Appreciation for Insmed (NASDAQ:INSM) Stock

Insmed (NASDAQ:INSM - Free Report) had its target price increased by Stifel Nicolaus from $88.00 to $97.00 in a report published on Tuesday morning,Benzinga reports. Stifel Nicolaus currently has a buy rating on the biopharmaceutical company's stock.

Other equities analysts have also issued reports about the company. Morgan Stanley boosted their price target on Insmed from $85.00 to $90.00 and gave the company an "overweight" rating in a research note on Thursday, February 6th. HC Wainwright reaffirmed a "buy" rating and set a $90.00 target price on shares of Insmed in a research report on Friday, November 1st. JPMorgan Chase & Co. upped their target price on Insmed from $83.00 to $92.00 and gave the stock an "overweight" rating in a research report on Friday, February 7th. Guggenheim upped their target price on Insmed from $95.00 to $101.00 and gave the stock a "buy" rating in a research report on Friday, February 7th. Finally, Truist Financial reaffirmed a "buy" rating and set a $105.00 target price (up from $100.00) on shares of Insmed in a research report on Friday, November 1st. One investment analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $85.60.

Insmed Trading Down 0.4 %

Shares of INSM stock traded down $0.32 during mid-day trading on Tuesday, reaching $78.35. 725,005 shares of the stock traded hands, compared to its average volume of 1,865,146. The stock's fifty day simple moving average is $73.23 and its two-hundred day simple moving average is $73.20. Insmed has a 1-year low of $21.92 and a 1-year high of $82.04. The company has a market cap of $14.02 billion, a price-to-earnings ratio of -14.12 and a beta of 1.11. The company has a quick ratio of 5.99, a current ratio of 6.37 and a debt-to-equity ratio of 2.03.

Insider Transactions at Insmed

In other news, CFO Sara Bonstein sold 1,066 shares of the firm's stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $63.72, for a total value of $67,925.52. Following the completion of the transaction, the chief financial officer now owns 118,863 shares in the company, valued at $7,573,950.36. This trade represents a 0.89 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 91,140 shares of the firm's stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $80.00, for a total value of $7,291,200.00. Following the completion of the transaction, the insider now owns 97,083 shares of the company's stock, valued at approximately $7,766,640. The trade was a 48.42 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 495,135 shares of company stock worth $38,409,713. 4.60% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Artia Global Partners LP raised its stake in Insmed by 217.2% during the fourth quarter. Artia Global Partners LP now owns 167,939 shares of the biopharmaceutical company's stock valued at $11,595,000 after buying an additional 115,000 shares during the last quarter. Aquatic Capital Management LLC raised its stake in shares of Insmed by 296.8% in the fourth quarter. Aquatic Capital Management LLC now owns 91,268 shares of the biopharmaceutical company's stock worth $6,301,000 after purchasing an additional 68,268 shares during the last quarter. Susquehanna Fundamental Investments LLC purchased a new position in shares of Insmed in the fourth quarter worth $18,707,000. Adage Capital Partners GP L.L.C. raised its stake in shares of Insmed by 59.6% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,647,562 shares of the biopharmaceutical company's stock worth $113,748,000 after purchasing an additional 615,000 shares during the last quarter. Finally, Syon Capital LLC purchased a new position in shares of Insmed in the fourth quarter worth $364,000.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.